176 related articles for article (PubMed ID: 25918282)
1. Carcinoid and neuroendocrine tumors: building on success.
Kunz PL
J Clin Oncol; 2015 Jun; 33(16):1855-63. PubMed ID: 25918282
[TBL] [Abstract][Full Text] [Related]
2. Nothing But NET: A Review of Neuroendocrine Tumors and Carcinomas.
Oronsky B; Ma PC; Morgensztern D; Carter CA
Neoplasia; 2017 Dec; 19(12):991-1002. PubMed ID: 29091800
[TBL] [Abstract][Full Text] [Related]
3. The spectrum of neuroendocrine tumors: histologic classification, unique features and areas of overlap.
Klimstra DS; Beltran H; Lilenbaum R; Bergsland E
Am Soc Clin Oncol Educ Book; 2015; ():92-103. PubMed ID: 25993147
[TBL] [Abstract][Full Text] [Related]
4. Recent updates on grading and classification of neuroendocrine tumors.
Kim JY; Hong SM; Ro JY
Ann Diagn Pathol; 2017 Aug; 29():11-16. PubMed ID: 28807335
[TBL] [Abstract][Full Text] [Related]
5. ENETS Consensus Guidelines Update for Gastroduodenal Neuroendocrine Neoplasms.
Delle Fave G; O'Toole D; Sundin A; Taal B; Ferolla P; Ramage JK; Ferone D; Ito T; Weber W; Zheng-Pei Z; De Herder WW; Pascher A; Ruszniewski P;
Neuroendocrinology; 2016; 103(2):119-24. PubMed ID: 26784901
[No Abstract] [Full Text] [Related]
6. Multidisciplinary management of advanced lung neuroendocrine tumors.
Filosso PL; Ferolla P; Guerrera F; Ruffini E; Travis WD; Rossi G; Lausi PO; Oliaro A;
J Thorac Dis; 2015 Apr; 7(Suppl 2):S163-71. PubMed ID: 25984363
[TBL] [Abstract][Full Text] [Related]
7. Dual inhibition of mTOR pathway and VEGF signalling in neuroendocrine neoplasms: from bench to bedside.
Cella CA; Minucci S; Spada F; Galdy S; Elgendy M; Ravenda PS; Zampino MG; Murgioni S; Fazio N
Cancer Treat Rev; 2015 Nov; 41(9):754-60. PubMed ID: 26142874
[TBL] [Abstract][Full Text] [Related]
8. Conservative management and parenchyma-sparing resections of pancreatic neuroendocrine tumors: Literature review.
Mauriello C; Napolitano S; Gambardella C; Candela G; De Vita F; Orditura M; Sciascia V; Tartaglia E; Lanza M; Santini L; Conzo G
Int J Surg; 2015 Sep; 21 Suppl 1():S10-4. PubMed ID: 26118605
[TBL] [Abstract][Full Text] [Related]
9. Consensus on biomarkers for neuroendocrine tumour disease.
Oberg K; Modlin IM; De Herder W; Pavel M; Klimstra D; Frilling A; Metz DC; Heaney A; Kwekkeboom D; Strosberg J; Meyer T; Moss SF; Washington K; Wolin E; Liu E; Goldenring J
Lancet Oncol; 2015 Sep; 16(9):e435-e446. PubMed ID: 26370353
[TBL] [Abstract][Full Text] [Related]
10. Gastroenteropancreatic Neuroendocrine Tumors.
Cives M; Strosberg JR
CA Cancer J Clin; 2018 Nov; 68(6):471-487. PubMed ID: 30295930
[TBL] [Abstract][Full Text] [Related]
11. Trends in the Incidence, Prevalence, and Survival Outcomes in Patients With Neuroendocrine Tumors in the United States.
Dasari A; Shen C; Halperin D; Zhao B; Zhou S; Xu Y; Shih T; Yao JC
JAMA Oncol; 2017 Oct; 3(10):1335-1342. PubMed ID: 28448665
[TBL] [Abstract][Full Text] [Related]
12. Neuroendocrine tumors of the pancreas: a retrospective single-center analysis using the ENETS TNM-classification and immunohistochemical markers for risk stratification.
Brunner SM; Weber F; Werner JM; Agha A; Farkas SA; Schlitt HJ; Hornung M
BMC Surg; 2015 Apr; 15():49. PubMed ID: 25928025
[TBL] [Abstract][Full Text] [Related]
13. Evolution in the treatment of gastroenteropancreatic-neuroendocrine neoplasms, focus on systemic therapeutic options: a systematic review.
Pusceddu S; De Braud F; Festinese F; Bregant C; Lorenzoni A; Maccauro M; Milione M; Concas L; Formisano B; Leuzzi L; Mazzaferro V; Buzzoni R
Future Oncol; 2015; 11(13):1947-59. PubMed ID: 26161929
[TBL] [Abstract][Full Text] [Related]
14. Temozolomide in Advanced Neuroendocrine Neoplasms: Pharmacological and Clinical Aspects.
Koumarianou A; Kaltsas G; Kulke MH; Oberg K; Strosberg JR; Spada F; Galdy S; Barberis M; Fumagalli C; Berruti A; Fazio N
Neuroendocrinology; 2015; 101(4):274-88. PubMed ID: 25924937
[TBL] [Abstract][Full Text] [Related]
15. Pazopanib and depot octreotide in advanced, well-differentiated neuroendocrine tumours: a multicentre, single-group, phase 2 study.
Phan AT; Halperin DM; Chan JA; Fogelman DR; Hess KR; Malinowski P; Regan E; Ng CS; Yao JC; Kulke MH
Lancet Oncol; 2015 Jun; 16(6):695-703. PubMed ID: 25956795
[TBL] [Abstract][Full Text] [Related]
16. Role of Somatostatin Analogues in the Treatment of Neuroendocrine Tumors.
Narayanan S; Kunz PL
Hematol Oncol Clin North Am; 2016 Feb; 30(1):163-77. PubMed ID: 26614375
[TBL] [Abstract][Full Text] [Related]
17. Gastrointestinal neuroendocrine tumors: Searching the optimal treatment strategy--A literature review.
Berardi R; Rinaldi S; Torniai M; Morgese F; Partelli S; Caramanti M; Onofri A; Polenta V; Pagliaretta S; Falconi M; Cascinu S
Crit Rev Oncol Hematol; 2016 Feb; 98():264-74. PubMed ID: 26643525
[TBL] [Abstract][Full Text] [Related]
18. Long-term results of PRRT in advanced bronchopulmonary carcinoid.
Mariniello A; Bodei L; Tinelli C; Baio SM; Gilardi L; Colandrea M; Papi S; Valmadre G; Fazio N; Galetta D; Paganelli G; Grana CM
Eur J Nucl Med Mol Imaging; 2016 Mar; 43(3):441-52. PubMed ID: 26392198
[TBL] [Abstract][Full Text] [Related]
19. AACE/ACE disease state clinical review: pancreatic neuroendocrine incidentalomas.
Herrera MF; Åkerström G; Angelos P; Grant CS; Hoff AO; Pantoja JP; Pérez-Johnston R; Sahani DV; Wong RJ; Randolph G
Endocr Pract; 2015 May; 21(5):546-53. PubMed ID: 25962093
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
